J VIROL:我国丙肝病毒疫苗研发取得突破

2016-11-11 佚名 中国医药报

导语:最近,中国科学院上海巴斯德研究所黄忠课题组与钟劲课题组合作,在丙型肝炎病毒(HCV)疫苗研究中取得突破性进展。其研究成果“糖基化类型的改变增强丙型肝炎病毒亚单位疫苗的免疫原性及保护性中和抗体的诱导能力”已在国际学术期刊Journal of Virology在线发表。最近,中国科学院上海巴斯德研究所黄忠课题组与钟劲课题组合作,在丙型肝炎病毒(HCV)疫苗研究中取得突破性进展。其研究成果“糖基化

导语:最近,中国科学院上海巴斯德研究所黄忠课题组与钟劲课题组合作,在丙型肝炎病毒(HCV)疫苗研究中取得突破性进展。其研究成果“糖基化类型的改变增强丙型肝炎病毒亚单位疫苗的免疫原性及保护性中和抗体的诱导能力”已在国际学术期刊Journal of Virology在线发表。

最近,中国科学院上海巴斯德研究所黄忠课题组与钟劲课题组合作,在丙型肝炎病毒(HCV)疫苗研究中取得突破性进展。其研究成果“糖基化类型的改变增强丙型肝炎病毒亚单位疫苗的免疫原性及保护性中和抗体的诱导能力”已在国际学术期刊Journal of Virology在线发表。

HCV感染是慢性肝炎的主要病因之一。目前全球有超过1.7亿例HCV感染病例,感染率为3%。在我国,HCV感染率为3.2%。病人感染HCV后80%转为慢性感染,其中10%~20%转归为肝硬化,1%~5%转归为肝癌。治疗性药物聚乙二醇干扰素联合利巴韦林只能治愈约50%的病人,尤其对1型HCV感染治疗效果较差;新一代药物DAAs的上市,将治愈率提高到90%以上,但新药价格极其昂贵而且存在产生耐药性的可能。因此,研制安全有效的预防性HCV疫苗,对于减轻这一全球性公共卫生负担,彻底解决丙肝问题具有重要意义。然而,由于HCV基因组的高频突变、包膜蛋白的糖基化、病毒颗粒被脂类分子包裹、非中和性抗体干扰等因素的影响,如何诱导产生能够中和全部7个病毒亚型的抗体一直是HCV疫苗研发的最大难点。目前还没有针对HCV的预防性疫苗上市。

上海巴斯德所博士研究生李大鹏等在研究员黄忠和钟劲的指导下,以HCV包膜蛋白E2为疫苗靶点,利用果蝇S2重组表达体系制备了可溶性E2蛋白(sE2),并系统评价了sE2疫苗的免疫原性、诱导广谱中和抗体能力及其在小鼠感染模型上的保护作用。结果表明,该sE2疫苗免疫小鼠能够诱导出针对全部7个亚型HCV的广谱中和抗体,更重要的是,上海巴斯德所团队与美国普林斯顿大学教授Alexander Ploss合作,确定了sE2疫苗在人源化小鼠模型中能够有效预防HCV感染,具有良好的免疫保护效果。

进一步的机制研究发现,昆虫细胞表达的sE2蛋白与来源于哺乳动物系统的抗原相比,其糖基化类型更为简单,而这种简单糖基化修饰对于sE2有效诱导广谱中和抗体是至关重要的。该项目所研发的sE2亚单位疫苗在诱导广谱中和抗体方面优于目前处于临床试验阶段的HCV候选疫苗,而且该疫苗成分简单、产量高,因此具有很好的产业化前景。(上海巴斯德研究所)

原始出处:




版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-13 忠诚向上

    好好学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-13 lqvr
  6. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-12 Peter程

    继续加油

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-11 忠诚向上

    好好学习

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-11 wxl882001

    好资料

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2077356, encodeId=fcd120e7356e8, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Fri Dec 09 21:29:00 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2083278, encodeId=1ad220832e8ed, content=<a href='/topic/show?id=b7cce09742a' target=_blank style='color:#2F92EE;'>#病毒疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70974, encryptionId=b7cce09742a, topicName=病毒疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1dbc2500219, createdName=huagfeg, createdTime=Thu Oct 19 02:29:00 CST 2017, time=2017-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1634311, encodeId=35af1634311b7, content=<a href='/topic/show?id=2346e05209f' target=_blank style='color:#2F92EE;'>#疫苗研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70520, encryptionId=2346e05209f, topicName=疫苗研发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce9922152235, createdName=lilili1111, createdTime=Sat Jun 17 04:29:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155384, encodeId=5ce615538497, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Nov 13 07:58:32 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1299964, encodeId=bae212999644b, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524128, encodeId=aa56152412846, content=<a href='/topic/show?id=c28320934ab' target=_blank style='color:#2F92EE;'>#丙肝病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20934, encryptionId=c28320934ab, topicName=丙肝病毒)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ef511588776, createdName=lujian, createdTime=Sun Nov 13 01:29:00 CST 2016, time=2016-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155224, encodeId=2bc015522447, content=继续加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1cdf1948157, createdName=Peter程, createdTime=Sat Nov 12 09:33:49 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155099, encodeId=6bb2155099c5, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Fri Nov 11 20:06:01 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=155010, encodeId=dc091550101d, content=好资料, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Fri Nov 11 13:09:59 CST 2016, time=2016-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=154999, encodeId=3ffd15499916, content=赞一个。疫苗研发不易,需要使劲。, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=2dd71722896, createdName=studylzc, createdTime=Fri Nov 11 12:56:15 CST 2016, time=2016-11-11, status=1, ipAttribution=)]
    2016-11-11 studylzc

    赞一个。疫苗研发不易,需要使劲。

    0

相关威廉亚洲官网

口服鸡尾酒Viekirax+Exviera 8周方案一线治疗GT1b丙肝治愈率高达98%

美国生物技术巨头艾伯维(AbbVie)近日公布了全口服丙肝鸡尾酒疗法Viekirax+Exviera一项IIIb期临床研究GARNET的新数据。该研究是一项多中心、开放标签、单组研究,在既往未接受治疗(初治)的无肝硬化基因型1b(GT1b)慢性丙型肝炎(HCV)患者中开展,调查了Viekirax+Exviera 8周治疗方案的疗效和安全性。该研究共招募了166例患者,其中163例为GT1b丙肝

我国丙肝防治多方面落后于乙肝

“我国丙肝防治在认知率、诊断率、治疗率以及药物可及性、可负担性等多方面都落后于乙肝。消除丙肝应以疾病教育为根本,同时从治疗突破,让患者在实现治愈的同时获益于生命质量的提升。”中国工程院院士、北京大学医学部庄辉教授在7月26日由吴阶平医学基金会、百时美施贵宝等共同举办的“世界肝炎日座谈会”上表示。7月28日是第六个世界肝炎日,今年世界肝炎日的主题是“同心协力,消除丙肝”。 世界卫生组织驻华代

丙肝重大进步!FDA批准吉利德全球泛基因型丙肝鸡尾酒Epclusa,治疗全部6种基因型丙肝

丙肝治疗领域的绝对霸主吉利德(Gilead)在研的一款泛基因型丙肝鸡尾酒疗法Epclusa近日在美国监管方面实现重大里程碑。FDA已批准Epclusa用于治疗全部6种基因型丙肝。此次批准,使Epclusa成为全球首个也是唯一一个全口服、泛基因型、单一片剂的丙肝治疗方案,该药同时也是吉利德开发的第3款基于sofosbuvir(索非布韦)的丙肝治疗药物。此外,Epclusa也是获批治疗基因型2和基因型

重磅!吉利德泛基因型丙肝鸡尾酒疗法Epclusa获英国NICE批准

近日,吉利德泛基因型丙肝鸡尾酒疗法Epclusa在英国监管方面收获重大利好消息,英国NICE发布威廉亚洲博彩公司 ,批准该药物在英格兰和威尔士患者中使用。 Epclusa在今年六月份被FDA批准,用于全部6种基因型丙肝,而在七月份,该药物也毫无悬念地拿下了欧洲的批文。 Epclusa是全球首个也是唯一一个全口服、泛基因型、单一片剂的丙肝治疗方案,该药同时也是吉利德开发的第3款基于sofosbuvir(索

丙肝病毒(HCV)研究进展

丙型肝炎由丙型肝炎病毒(HCV)感染所致,主要由血液/体液传播。据世界卫生组织估计,全球有1.7亿人感染HCV。在我国健康人群抗HCV阳性率为0.7%~3.1%,约3800万人。由于病毒生物学特点和宿主免疫功能等多方面因素,机体免疫往往难以有效清除病毒,致使约50%~80%HCV感染者发展为慢性肝炎,其中20%~30%将发展成肝硬化。肝硬化患者中每年有1%~4%发展成为肝细胞癌症。

丙肝重大里程碑!吉利德全球泛基因型丙肝鸡尾酒Epclusa获美国和欧盟批准!

丙肝治疗领域的绝对霸主吉利德(Gilead)开发的泛基因型丙肝鸡尾酒疗法Epclusa在美国和欧盟监管方面均实现重大里程碑。美国方面,FDA于上月底批准Epclusa用于治疗全部6种基因型丙肝。而就在最近,Epclusa也毫无悬念地获得欧盟委员会(EC)批准用于治疗全部6种基因型丙肝。 此次批准,使Epclusa成为全球首个也是唯一一个全口服、泛基因型、单一片剂的丙肝治疗方案,该药同时也是吉利德